Anebulo Pharmaceuticals

ANEB · OTC

$0.295+$0.2943 (+42042.86%)TodayMarket closed · Oct 20, 10:39 AM ET

No price history for this range.

ANEB analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Mar 20, 2025

Bull case

Anebulo Pharmaceuticals Inc is poised for potential upward momentum due to anticipated positive milestones surrounding its lead product candidate, ANEB-001, which addresses the increasing concern of cannabinoid overdose amid rising THC potency and legalization efforts. The company’s market opportunity is further bolstered by a $1.9 million cooperative grant from NIDA to develop an intravenous formulation of ANEB-001, highlighting regulatory support for its innovative approach. Clinical studies demonstrate that ANEB-001 is rapidly absorbed, well tolerated, and effectively contributes to weight loss, reinforcing its viability in treating acute cannabis overdose and enhancing the company’s growth potential.

Bear case

Anebulo Pharmaceuticals has experienced a significant decline in share value since its Initial Public Offering in May 2021, reflecting broader market trends. The company is projected to incur a net loss of $5.6 million for fiscal 2025, which represents a continuing trend of financial losses, including a reported net loss of $8.2 million for the fiscal year ending June 2024. Additionally, the decrease in losses from $11.7 million in fiscal 2023 to $8.2 million in fiscal 2024 indicates only a marginal improvement, which may raise concerns about the company’s financial sustainability and growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.